Among F3T3-positive tumors with analyzable data, 78.1% (25/32) had concurrent chromosome 7 gain and 10q loss, 9.4% (3/32) had chromosome 7 gain without 10q loss, 6.3% (2/32) had 10q loss without chromosome 7 gain, and 6.3% (2/32) had concurrent loss of 10q, 13q, and 14q, all consistent with the integrated diagnosis of IDH-wildtype GBM. The gene discussed is IDH2; the disease is glioblastoma.